ArticleIndian journal of sexually transmitted diseases and AIDS
Challenges in status disclosure and adherence to antiretroviral therapy in children living with HIV: An observational study.
Article in Indian journal of sexually transmitted diseases and AIDS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: The advent of highly active antiretroviral therapy has increased the longevity in children living with HIV (CLHIV), which has brought forth new concerns related to status disclosure and adherence to treatment. Information regarding this is limited in Punjab; hence, this study was done to find the relation of disclosure with sociodemographic factors and the problems faced in adhering to antiretroviral therapy (ART) in this region. Materials and Methods: An observational cross-sectional study was conducted on CLHIVs aged 18 months to 15 years visiting the ART center of a tertiary hospital from June to December 2021. Willing caregivers were approached with semistructured validated pretested questionnaire developed for the study. Results: Ninety-eight caregivers of CLHIV were interviewed and 25% were found to be aware of their serostatus. Children between 5 and 12 years comprised the largest group (57%) and this was also the statistically significant age group in whom the status was not disclosed. Disclosure was more in children having single parents. The low economic status, rural background, and low education status of the caregivers were inversely related to disclosure. Sixty-five percent of the caregivers believed that the appropriate age for status disclosure should be 14-18 years. Adherence was optimal in 85% CLHIVs and distance was the foremost challenge. Conclusion: The mean age for disclosure was found to be higher than the World Health Organization guidelines in this study; hence, there is a need to encourage caregivers for timely and systematic disclosure and motivate them for maintaining optimal adherence in CLHIV which is important for the success of ART program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.